JCAR 020

Drug Profile

JCAR 020

Alternative Names: Anti MUC-16 chimeric antigen receptor T-cell therapy; Anti-MUC16 CAR-T cell therapy-Juno; IL-12-secreting MUC-16 CAR-T cell therapy; JCAR020; MUC-16-IL-12 armored CAR-T-cells; MUC-16-IL-12-armored chimeric antigen receptor T-cells

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Ovarian cancer

Most Recent Events

  • 13 Apr 2018 JCAR 020 is still in phase I trials for Ovarian cancer in USA
  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Ovarian-cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top